Short Interest in enGene Holdings Inc. (NASDAQ:ENGNW) Expands By 46.1%

enGene Holdings Inc. (NASDAQ:ENGNW) was the target of a large growth in short interest during the month of May. As of May 15th, there was short interest totalling 39,600 shares, a growth of 46.1% from the April 30th total of 27,100 shares. Based on an average trading volume of 7,700 shares, the days-to-cover ratio is presently 5.1 days.

enGene Price Performance

Shares of NASDAQ ENGNW traded up $0.05 during trading hours on Monday, reaching $0.80. 300 shares of the stock were exchanged, compared to its average volume of 9,572. The stock’s fifty day simple moving average is $0.67 and its 200 day simple moving average is $0.88. enGene has a 52 week low of $0.42 and a 52 week high of $3.46.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.